

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
30th October 2025

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Manager Ami Kira

(Delayed)Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2025

Kanagawa Japan

30th October 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) held a “Financial Results Briefing for the Period Ending August 2025” on Tuesday, October 14, 2025, and the transcript of the event (including the Q&A session) has been published on Logmi Finance. We believe that this will help to bridge the information gap between investors and the company and lead to a deeper understanding of our business, and we will continue to strive for fair information disclosure.

1. Overview

Date : Tuesday, October 14, 2025, 15:30 - 16:30 (JST)
Presenter : Hiroshi Miyake, Chief Executive Officer
Method of holding : Web-based

2. Transcript article URL

<https://finance.logmi.jp/en/articles/383071>
Media management company : Logmi, Inc.

About Chordia Therapeutics

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.